Notably, mechanisms underlying oncogene-mediated activation of p53 appear to be more active in CLs and basal-like tumours, as evidenced by the upregulation in both groups of CDKN2A—which indirectly activates p53 by repressing MDM236,37. Here, CDKN2A is linked to neoplasm.